Table 2. Statistic analysis of the correlation of Tyr31- phosphorylated paxillin [PXN (p-Y31)] with Metastatic potentials of HCC.
| Metastatic potentials | PXN (p-Y31) | P value* | ||
|---|---|---|---|---|
| All cases | Low expression (T < N) | High expression (T > N) | ||
| Intra-hepatic Metastasis | ||||
| Positive | 18 | 5 (27.8%) | 13 (72.2%) | 0.004 |
| Negative | 127 | 81 (63.8%) | 46 (36.2%) | |
| Extra-hepatic Metastasis | ||||
| Positive | 6 | 2 (33.3%) | 4 (66.7%) | 0.186 |
| Negative | 139 | 84 (60.4%) | 55 (39.6%) | |
| Total Metastasis | ||||
| Positive | 19 | 6 (31.6%) | 13 (68.4%) | 0.008 |
| Negative | 126 | 80 (63.5%) | 46 (36.5%) | |
PXN (p-Y31) in HCC tissue (T) lower than that in the normal counterpart (N) by over 1.5–2.0 fold.
PXN (p-Y31) in HCC tissue (T) higher than that in the normal counterpart (N) by over 1.5–2.0 fold.
Statistical significance between high PXN (p-Y31) with indicated metastatic potential estimated by Chi-square test
Sites of intra-hepatic metastasis (I.M.) coupled with vascular invasion in liver, including microscopic vascular invasion in small vessels and macroscopic tumor invasion in bile duct, hepatic vein and portal vein can be observed
Extra-hepatic metastasis (E.M.) including regional lymph node metastasis and distant organ metastasis can be observed
Total Metastasis is equal to the summation of I.M. and E.M.
The percentage in parenthesis represent the ratio of the number of HCCs with indicated PXN (p-Y31) status (ie. T < N or T > N) vs total number of HCCs (all case) classified as either positive or negative of the indicated metastatic potential.